GLP-1 HRAs
Medical cost trends have risen by 10% since 2022. But the cost trend for Rx is over 17% for the same period. Much of this increase in Rx is due to exploding sales for GLP-1s (such as Ozempic, Wegovy, Zepbound and Rubelsus) for use as weight loss drugs, driving costs to unsustainable levels for both insured and self-insured plans. Because over 45% of GLP-1 prescriptions now flow outside of the traditional PBM/retail pharmacy ecosystem, controlling eligibility is key to controlling costs.
There have been court challenges to this action. However, the First Circuit Court of Appeals handed down a decision in late April (Holland v. Elevance Health, Inc., 2026 WL 850818) that affirmed a lower court’s ruling rejecting the claim that removing these drugs violated ACA Section 1557’s anti-discrimination provisions.
Many employers have removed GLP-1s from their Rx formulary and use a GLP-1 HRA to maintain employee access to GLP-1s while controlling costs.
A GLP-1 HRA is an employer-funded Health Reimbursement Arrangement designed to specifically cover the costs of GLP-1 medications while managing skyrocketing employer expenses. It allows employers to cap their financial liability by setting a defined, annual or quarterly maximum reimbursement amount rather than having an open-ended pharmacy cost. Employees usually pay for the medication up-front (particularly with direct-to-consumer pharmacy pricing options) and submit claims to be reimbursed by the HRA. Coverage is often restricted to specific conditions, such as Type 2 diabetes or documented obesity, and may require a showing of medical necessity and/or adherence to a managed weight-loss program.
GLP-1 HRAs are just one of many innovative programs that employers are using to cope with exploding cost trends.
The information in this blog post is for educational purposes only. It is not investment, legal or tax advice. For legal or tax advice, you should consult your own counsel. To stay up to date on benefits trends and insights, subscribe to our blog.